BACKGROUND
The coronavirus disease 2019 (COVID-19) pandemic is an ongoing global health crisis caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Intervening early in the disease course by antivirals can delay progression and improve clinical outcomes. Since Direct-acting antivirals (DAAs) changed the entire landscape of hepatitis C (HCV) treatment, there has been considerable interest with these DAAs, such as sofosbuvir and daclatasvir, as new repurposed options in COVID-19 therapeutics .
OBJECTIVE
This study is carried out to determine whether sofosbuvir/daclatasvir-based regimens improve clinical outcomes of patients with moderate or severe COVID-19.
METHODS
This was a prospective study including patients with PCR- confirmed COVID-19, that were treated with sofosbuvir and Daklatasvir- based regimen for 14 days. Results: Demographic data of the included 54 patients: Male (57%), female (43%), age <50 years (48%), > 50 years (52%), smoking (9%), diabetes mellitus (9%) and hypertension in 28% of patients. Clinical presentation of COVID-19: Fever (87%), cough (97%), dyspnea (70%), chest pain (61%), sore throat (53%), diarrhea (50%), mood changes (43%), muscle pain (87%), oxygen saturation median (93.5 +/- 5.5 %), and CT chest changes indicating COVID-19 was received in (55%) of patients. Laboratory data: PCR for Covid-19 was positive in (100%) , CRP was positive in (87%).
RESULTS
Complete recovery was observed in 100%, and none of the patients progressed to severe stage.
CONCLUSIONS
Conclusions: Sofosbuvir/ daclatasvir- based regimen is highly effective and safe in curing patients with Covid-19, preventing progression to severe stage as well as in decreasing mortality.
CLINICALTRIAL
The study has been approved by Faculty of Medicine- Alexandria University Ethics Committee (IRB No: 00012098) according to Ethical standards of scientific research.